Business Description
Sinovac Biotech Ltd
ISIN : AGP8696W1045
Total Employee Number:
2,602Compare
Compare
Traded in other countries / regions
SVA.USASVQ.Germany Index Membership
NASDAQ Golden Dragon China IndexNASDAQ Golden Dragon China IndexNASDAQ Golden Dragon China IndexNASDAQ Golden Dragon China Index IPO Date
2003-09-26Description
Sinovac Biotech Ltd is a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with unmet medical needs. It has developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus. The Company operates exclusively in the research, development, manufacture, and commercialization of vaccines sector. The Company's business is considered as operating in one segment. It has presence in Chinese Mainland, and Outside Chinese Mainland.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 11.81 | |||||
Equity-to-Asset | 0.52 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | -3.34 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.31 | |||||
Beneish M-Score | -2.3 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -25.7 | |||||
3-Year FCF Growth Rate | 8.8 | |||||
3-Year Book Growth Rate | -11.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.59 | |||||
Quick Ratio | 4.53 | |||||
Cash Ratio | 3.88 | |||||
Days Inventory | 294.64 | |||||
Days Sales Outstanding | 281.8 | |||||
Days Payable | 606.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 10.3 | |||||
Shareholder Yield % | -27.48 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 67.87 | |||||
Operating Margin % | -74.42 | |||||
Net Margin % | -15.46 | |||||
EBITDA Margin % | -39.18 | |||||
FCF Margin % | -145.41 | |||||
OCF Margin % | -132.69 | |||||
ROE % | -1.05 | |||||
ROA % | -0.54 | |||||
ROIC % | -11.92 | |||||
3-Year ROIIC % | -78.65 | |||||
ROC (Joel Greenblatt) % | -30.38 | |||||
ROCE % | -3.04 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio without NRI | 6.24 | |||||
Shiller PE Ratio | 0.81 | |||||
PS Ratio | 1.2 | |||||
PB Ratio | 0.1 | |||||
Price-to-Tangible-Book | 0.11 | |||||
EV-to-EBIT | 12.08 | |||||
EV-to-EBITDA | 20.15 | |||||
EV-to-Revenue | -7.9 | |||||
EV-to-FCF | 5.43 | |||||
Price-to-Projected-FCF | 0.02 | |||||
Price-to-Median-PS-Value | 0.74 | |||||
Price-to-Graham-Number | 0.17 | |||||
| Price-to-Net-Current-Asset-Value | 0.16 | |||||
| Price-to-Net-Cash | 0.25 | |||||
Earnings Yield (Greenblatt) % | 8.28 | |||||
FCF Yield % | -121.96 | |||||
Forward Rate of Return (Yacktman) % | 305.66 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SVA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sinovac Biotech Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 386.013 | ||
| EPS (TTM) ($) | -0.83 | ||
| Beta | 1.1191 | ||
| 3-Year Sharpe Ratio | -59.39 | ||
| 3-Year Sortino Ratio | -3.46 | ||
| Volatility % | 850.08 | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | - | ||
| 20-Day SMA ($) | 6.47 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 6.47 - 6.47 | ||
| Shares Outstanding (Mil) | 71.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sinovac Biotech Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sinovac Biotech Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2025 | 2026-07-06 | In 1 day | ||
| Second quarter earnings results for 2025 | 2026-05-09 | 6.47 (+0.00%) | ||
| Annual report for 2025 | 2026-04-30 | 6.47 (+0.00%) | ||
| USD 55.000000 Cash Dividend | 2025-07-08 | 6.47 (+0.00%) | ||
| Second quarter earnings results for 2024 | 2024-08-16 | 6.47 (+0.00%) |
Show
Entries
Sinovac Biotech Ltd Frequently Asked Questions
What is Sinovac Biotech Ltd(SVA)'s stock price today?
The current price of SVA is $6.47. The 52 week high of SVA is $6.47 and 52 week low is $6.47.
When is next earnings date of Sinovac Biotech Ltd(SVA)?
The next earnings date of Sinovac Biotech Ltd(SVA) is 2026-11-09 Est..
Does Sinovac Biotech Ltd(SVA) pay dividends? If so, how much?
Sinovac Biotech Ltd(SVA) does not pay dividend.
Guru Commentaries on NAS:SVA
No articles.
Press Release
Articles on Sinovac Biotech Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers